Tijana Martinov

The Parker Institute for Cancer Immunotherapy recently welcomed seven talented early career researchers in cancer immunotherapy to its network as part of the Parker Scholars, Parker Bridge Scholars and Parker Fellows programs. These researchers will receive a total of up to $3.1 million in funding and the opportunity to train with top scientists in the field, to support them as they embark on their research to move the field forward.

“We continue to train and invest in the next generation of researchers because they are the future of cancer immunotherapy research,” said Jeffrey Bluestone, Ph.D., president and CEO of the Parker Institute. “By giving them the opportunity to take risks, explore novel concepts and collaborate with pioneers in the field, we can work with them to push the boundaries of their research and get treatments to patients faster.”